Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Letter to the Editor

Early Detection of Hepatitis E Virus Ribavirin Resistance Using Next-Generation Sequencing

Florian Gerhardt, Melanie Maier, U. G. Liebert, Uwe Platzbecker, Song-Yau Wang, Christian Patrick Papp, C. Thomas Bock, Thomas Berg, Florian van Bömmel
Florian Gerhardt
aDepartment for Gastroenterology, Section of Hepatology, University Hospital Leipzig AöR, Leipzig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melanie Maier
bInstitute of Virology, University Hospital Leipzig AöR, Leipzig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
U. G. Liebert
bInstitute of Virology, University Hospital Leipzig AöR, Leipzig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uwe Platzbecker
dMedical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig AöR, Leipzig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Song-Yau Wang
dMedical Clinic and Policlinic 1, Hematology and Cellular Therapy, University Hospital Leipzig AöR, Leipzig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Patrick Papp
cViral Gastroenteritis and Hepatitis Pathogens and Enteroviruses, Robert Koch-Institute Berlin, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Thomas Bock
cViral Gastroenteritis and Hepatitis Pathogens and Enteroviruses, Robert Koch-Institute Berlin, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for C. Thomas Bock
Thomas Berg
aDepartment for Gastroenterology, Section of Hepatology, University Hospital Leipzig AöR, Leipzig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Florian van Bömmel
aDepartment for Gastroenterology, Section of Hepatology, University Hospital Leipzig AöR, Leipzig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Florian van Bömmel
DOI: 10.1128/AAC.01525-19
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

LETTER

Treating chronic hepatitis E virus (HEV) infections with ribavirin (RBV) is a recommended option (1).

With great interest, we read the article of Lhomme and coworkers, who described the influence of the HEV variant G1634R to RBV treatment in immunocompromised patients. The presence of G1634R in the individuals assessed by Lhomme et al. did not lead to absolute RBV resistance and did not compromise the response to a second RBV treatment (2). The role of G1634R and other variants for clinical HEV resistance against RBV is under discussion (3–6). Here, we report a longitudinal observation of clinical RBV-induced mutations associated with increasing selection of the variant G1634R in an immunocompromised patient.

Our 62-year-old male patient had undergone allogeneic stem cell transplantation (aSCT) in 2012 for primary myelofibrosis. During 4 years, he received a combination of prednisolone, cyclosporine, and mycophenolic acid for suspected chronic graft-versus-host disease. An HEV infection with genotype 3c and HEV RNA level of 5,570,000 IU/ml was first diagnosed in May 2016.

Oral treatment with RBV (1,200 mg/day) was conducted for 3 months. Subsequently, alanine transaminase (ALT) levels normalized, and HEV RNA decreased rapidly to undetectable levels within 4 weeks (Fig. 1). RBV treatment was stopped after 3 months, as previously proposed (7). Unexpectedly, shortly thereafter, HEV RNA reappeared, and ALT levels reincreased. Therefore, we decided to reinitiate RBV treatment.

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

Courses of HEV RNA in blood serum and stool, HEV variants detected in serum, and ALT levels before and during ribavirin treatment in an immunosuppressed patient. Amino acids are displayed in green for the wild type and in red for resistance-associated variants and are given in ratios for next-generation sequencing (NGS) results. The percentage refers to the mutation. HEV RNA, hepatitis E virus RNA (continued line, lower limit of detection 250 IU/ml in serum; dots, lower limit of detection 250 IU/ml in stool); RBV, ribavirin; ALT, alanine transaminase; dashed line, upper limit of normal of alanine transaminase.

Consecutively, HEV RNA became again undetectable, and ALT levels normalized (Fig. 1). However, as HEV reappeared during treatment, we decided to discontinue RBV to prevent a possible further selection of resistant variants. Instead, we reduced the immunosuppression, which was followed by a durable decrease in HEV RNA levels. ALT levels temporarily increased after resolution of the HEV infection, which we interpreted as a sign of immune reconstitution.

Using Sanger sequencing of the RNA-dependent RNA polymerase (RdRp) region of the HEV genome (open reading frame 1 [ORF1]), the HEV wild type was found at baseline. However, after the first rebound, the RBV-induced mutations K1383N, G1634R Y1320H, D1384G, K1398R, V1479I, and Y1587 could be detected (Fig. 1). After the second rebound and thereafter, RBV-induced mutations showed increasing frequency. To investigate a possible presence of RBV-induced mutations before exposure to RBV, we sequenced the HEV genome from the baseline sample on the MiSeq platform (Illumina, San Diego, CA, USA). Intriguingly, by this approach, we could detect the K1383N and G1634R variants even before the initiation of RBV treatment (Fig. 1; for methods, see the supplemental material).

In accordance with Lhomme and colleagues, we feel that the significance of the presence of RBV-induced mutations before treatment is uncertain. However, we could show that treatment monitoring may reveal a selection of those variants and allow the early prediction of clinical resistance. It needs to be further investigated if there is a threshold of RBV-resistant variants that make a viral breakthrough more likely, and if those patients may have stronger benefit from other treatment options, e.g., modification of the immune suppression or sofosbuvir treatment, although this treatment is to date not evidence based.

FOOTNOTES

    • Accepted manuscript posted online 4 November 2019.
  • Supplemental material is available online only.

  • Copyright © 2019 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Dalton HR,
    2. Kamar N,
    3. Baylis SA,
    4. Moradpour D,
    5. Wedemeyer H,
    6. Negro F
    . 2018. EASL clinical practice guidelines on hepatitis E virus infection. J Hepatol 68:1256–1271. doi:10.1016/j.jhep.2018.03.005.
    OpenUrlCrossRef
  2. 2.↵
    1. Lhomme S,
    2. Kamar N,
    3. Nicot F,
    4. Ducos J,
    5. Bismuth M,
    6. Garrigue V,
    7. Petitjean-Lecherbonnier J,
    8. Ollivier I,
    9. Alessandri-Gradt E,
    10. Goria O,
    11. Barth H,
    12. Perrin P,
    13. Saune K,
    14. Dubois M,
    15. Carcenac R,
    16. Lefebvre C,
    17. Jeanne N,
    18. Abravanel F,
    19. Izopet J
    . 2015. Mutation in the hepatitis E virus polymerase and outcome of ribavirin therapy. Antimicrob Agents Chemother 60:1608–1614. doi:10.1128/AAC.02496-15.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Debing Y,
    2. Gisa A,
    3. Dallmeier K,
    4. Pischke S,
    5. Bremer B,
    6. Manns M,
    7. Wedemeyer H,
    8. Suneetha PV,
    9. Neyts J
    . 2014. A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients. Gastroenterology 147:1008–1011.e7. doi:10.1053/j.gastro.2014.08.040.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Debing Y,
    2. Ramière C,
    3. Dallmeier K,
    4. Piorkowski G,
    5. Trabaud MA,
    6. Lebossé F,
    7. Scholtès C,
    8. Roche M,
    9. Legras-Lachuer C,
    10. de Lamballerie X,
    11. André P,
    12. Neyts J
    . 2016. Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity. J Hepatol 65:499–508. doi:10.1016/j.jhep.2016.05.002.
    OpenUrlCrossRef
  5. 5.↵
    1. Todt D,
    2. Meister TL,
    3. Steinmann E
    . 2018. Hepatitis E virus treatment and ribavirin therapy: viral mechanisms of nonresponse. Curr Opin Virol 32:80–87. doi:10.1016/j.coviro.2018.10.001.
    OpenUrlCrossRef
  6. 6.↵
    1. van Tong H,
    2. Hoan NX,
    3. Wang B,
    4. Wedemeyer H,
    5. Bock CT,
    6. Velavan TP
    . 2016. Hepatitis E virus mutations: functional and clinical relevance. EBioMedicine 11:31–42. doi:10.1016/j.ebiom.2016.07.039.
    OpenUrlCrossRef
  7. 7.↵
    1. Kamar N,
    2. Izopet J,
    3. Tripon S,
    4. Bismuth M,
    5. Hillaire S,
    6. Dumortier J,
    7. Radenne S,
    8. Coilly A,
    9. Garrigue V,
    10. D'Alteroche L,
    11. Buchler M,
    12. Couzi L,
    13. Lebray P,
    14. Dharancy S,
    15. Minello A,
    16. Hourmant M,
    17. Roque-Afonso A-M,
    18. Abravanel F,
    19. Pol S,
    20. Rostaing L,
    21. Mallet V
    . 2014. Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med 370:1111–1120. doi:10.1056/NEJMoa1215246.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Download PDF
Citation Tools
Early Detection of Hepatitis E Virus Ribavirin Resistance Using Next-Generation Sequencing
Florian Gerhardt, Melanie Maier, U. G. Liebert, Uwe Platzbecker, Song-Yau Wang, Christian Patrick Papp, C. Thomas Bock, Thomas Berg, Florian van Bömmel
Antimicrobial Agents and Chemotherapy Dec 2019, 64 (1) e01525-19; DOI: 10.1128/AAC.01525-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Early Detection of Hepatitis E Virus Ribavirin Resistance Using Next-Generation Sequencing
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Early Detection of Hepatitis E Virus Ribavirin Resistance Using Next-Generation Sequencing
Florian Gerhardt, Melanie Maier, U. G. Liebert, Uwe Platzbecker, Song-Yau Wang, Christian Patrick Papp, C. Thomas Bock, Thomas Berg, Florian van Bömmel
Antimicrobial Agents and Chemotherapy Dec 2019, 64 (1) e01525-19; DOI: 10.1128/AAC.01525-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • LETTER
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

hepatitis E
ribavirin
viral hepatitis

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596